Stock listing
BEAM Stock Price, News, Filings & Events — Beam Therapeutics Inc.
Selected listing: BEAM · BIVA · MXN · MX
This page tracks Beam Therapeutics Inc.'s BEAM:BIVA listing on BIVA in MXN for MX, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following BEAM:BIVA. BEAM:BIVA is the stock-level entry point for investors researching Beam Therapeutics Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Beam Therapeutics Inc. is a public company traded under the ticker BEAM in the American market. The company has a market capitalization of approximately $2.58 billion. Beam Therapeutics focuses on developing precision genetic medicines to treat various diseases.
- Ticker
- BEAM:BIVA
- Asset type
- Stock
- Market cap
- $3.07B
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- BIVA
- Currency
- MXN
Beam Therapeutics Inc. BEAM:BIVA stock context
This page tracks Beam Therapeutics Inc.'s BEAM:BIVA listing on BIVA in MXN for MX, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following BEAM:BIVA. BEAM:BIVA is the stock-level entry point for investors researching Beam Therapeutics Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Beam Therapeutics Inc. is a public company traded under the ticker BEAM in the American market. The company has a market capitalization of approximately $2.58 billion. Beam Therapeutics focuses on developing precision genetic medicines to treat various diseases.
Latest news from Beam Therapeutics Inc.
Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer
September 1, 2026
Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences
August 31, 2026
Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Tr...
August 4, 2026
Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral...
July 23, 2026
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by ...
June 18, 2026
Beam Therapeutics Inc. earnings calls
Research Beam Therapeutics Inc.
Beam Therapeutics Inc. investor report
Review AI stock analysis and investor report context for BEAM:BIVA.
Beam Therapeutics Inc. company profile
View the public company page for Beam Therapeutics Inc. on 6ix.
Beam Therapeutics Inc. news
Read company news and market updates connected to Beam Therapeutics Inc..
Beam Therapeutics Inc. investor events
Find investor webinars, events, and replay context for Beam Therapeutics Inc..
Alternate listings
BEAM:NASDAQ
US · USD
Alternate listing for Beam Therapeutics Inc.; the primary context on this page is BEAM:BIVA.
BEAM:BMV
MX · MXN
Alternate listing for Beam Therapeutics Inc.; the primary context on this page is BEAM:BIVA.
BEAM:BOATS
US · USD
Alternate listing for Beam Therapeutics Inc.; the primary context on this page is BEAM:BIVA.